India Pharma Industry Floats Ombudsman As Way To Curb Unfair Marketing Practices
This article was originally published in PharmAsia News
Executive Summary
Indian industry pushes for self-regulation in effort to ward off new regulations.
You may also be interested in...
Indian Regulators Warn Companies Against “Unethical Promotion” Of Drugs To Doctors
MUMBAI - India's drug price regulatory body, the National Pharmaceutical Pricing Authority, has come down heavily on perpetrators of "unethical promotion of drugs" to medical practitioners, adding that such moves push up drug prices, making them unaffordable to the masses
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.